Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial

BACKGROUND: Allogeneic hematopoietic stem cell transplantation (HSCT), the most widely used potentially curable cellular immunotherapeutic approach in the treatment of hematological malignancies, is limited by life-threatening complications: graft versus host disease (GVHD) and infections especially...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Chongsheng, Campidelli, Arnaud, Wang, Yingying, Cai, Huili, Venard, Véronique, Jeulin, Hélène, Dalle, Jean Hugues, Pochon, Cécile, D’aveni, Maud, Bruno, Benedicte, Paillard, Catherine, Vigouroux, Stéphane, Jubert, Charlotte, Ceballos, Patrice, Marie-Cardine, Aude, Galambrun, Claire, Cholle, Clément, Clerc Urmes, Isabelle, Petitpain, Nadine, De Carvalho Bittencourt, Marcelo, Decot, Véronique, Reppel, Loïc, Salmon, Alexandra, Clement, Laurence, Bensoussan, Danièle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421327/
https://www.ncbi.nlm.nih.gov/pubmed/28482908
http://dx.doi.org/10.1186/s13045-017-0469-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421327/
https://www.ncbi.nlm.nih.gov/pubmed/28482908
http://dx.doi.org/10.1186/s13045-017-0469-0

Ejemplares similares